Abstract
The DNA sequence specificity of the cancer chemotherapeutic agent, bleomycin, was determined with high precision in purified plasmid DNA using an improved technique. This improved technique involved the labelling of the 5′- and 3′-ends of DNA with different fluorescent tags, followed by simultaneous cleavage by bleomycin and capillary electrophoresis with laser-induced fluorescence. This permitted the determination of bleomycin cleavage specificity with high accuracy since end-label bias was greatly reduced. Bleomycin produces single- and double-strand breaks, abasic sites and other base damage in DNA. This high-precision method was utilised to elucidate, for the first time, the DNA sequence specificity of bleomycin-induced DNA damage at abasic sites. This was accomplished using endonuclease IV that cleaves DNA at abasic sites after bleomycin damage. It was found that bleomycin-induced abasic sites formed at 5′-GC and 5′-GT sites while bleomycin-induced phosphodiester strand breaks formed mainly at 5′-GT dinucleotides. Since bleomycin-induced abasic sites are produced in the absence of molecular oxygen, this difference in DNA sequence specificity could be important in hypoxic tumour cells.
Similar content being viewed by others
Abbreviations
- CE-LIF:
-
Capillary electrophoresis with laser-induced fluorescence
- dNTP:
-
Deoxynucleotide triphosphates
- FAM-dUTP:
-
Aminoallyl-dUTP-6-FAM
- Rb1:
-
Human retinoblastoma 1 gene
References
Stoter G, Kaye SB, de Mulder PH, Levi J, Raghavan D (1994) J Clin Oncol 12:644–645
Einhorn LH (2002) Proc Natl Acad Sci USA 99:4592–4595
Umezawa H, Maeda K, Takeuchi T, Okami Y (1966) J Antibiot 19:200–209
Mirabelli CK, Huang CH, Fenwick RG, Crooke ST (1985) Antimicrob Agents Chemother 27:460–467
Sikic BI (1986) Cancer Surv 5:81–91
Chen J, Stubbe J (2005) Nat Rev Cancer 5:102–112
Burger RM (1998) Chem Rev 98:1153–1170
Burger RM, Berkowitz AR, Peisach J, Horwitz SB (1980) J Biol Chem 255:11832–11838
Giloni L, Takeshita M, Johnson F, Iden C, Grollman AP (1981) J Biol Chem 256:8608–8615
Povirk LF, Han YH, Steighner RJ (1989) Biochemistry 28:5808–5814
Stubbe J, Kozarich JW, Wu W, Vanderwall DE (1996) Acc Chem Res 29:322–330
Rabow LE, Stubbe J, Kozarich JW (1990) J Am Chem Soc 112:3196–3203
Takeshita M, Grollman AP, Ohtsubo E, Ohtsubo H (1978) Proc Natl Acad Sci USA 75:5983–5987
Takeshita M, Kappen LS, Grollman AP, Eisenberg M, Goldberg IH (1981) Biochemistry 20:7599–7606
D’Andrea AD, Haseltine WA (1978) Proc Natl Acad Sci USA 75:3608–3612
Kross J, Henner WD, Hecht SM, Haseltine WA (1982) Biochemistry 21:4310–4318
Mirabelli CK, Ting A, Huang CH, Mong S, Crooke ST (1982) Cancer Res 42:2779–2785
Murray V, Martin RF (1985) Nucleic Acids Res 13:1467–1481
Murray V, Tan L, Matthews J, Martin RF (1988) J Biol Chem 263:12854–12859
Nightingale KP, Fox KR (1993) Nucleic Acids Res 21:2549–2555
Murray V (2000) Prog Nucl Acid Res Mol Biol 63:367–415
Murray V, Martin RF (1985) J Biol Chem 260:10389–10391
Cairns MJ, Murray V (1996) Biochemistry 35:8753–8760
Kim A, Murray V (2000) Int J Biochem Cell Biol 32:695–702
Kim A, Murray V (2001) Int J Biochem Cell Biol 33:1183–1192
Temple MD, Freebody J, Murray V (2004) Biochim Biophys Acta 1678:126–134
Temple MD, Murray V (2005) Int J Biochem Cell Biol 37:665–678
Nguyen HTQ, Murray V (2012) J Biol Inorgan Chem 17:1209–1215
Murray V, Chen JK, Galea AM (2014) Cell Mol Life Sci 71:1505–1512
Kuo MT, Hsu TC (1978) Nature 271:83–84
Galea AM, Murray V (2010) Chem Biol Drug Design 75:578–589
Murray V, Chen JK, Galea AM (2014) Mutat Res Fundal Mol Mech Mutagen 769:93–99
Paul M, Murray V (2012) Biomed Chromat 26:350–354
Nguyen TV, Murray V (2012) J Biol Inorgan Chem 17:1–9
Murray V, Nguyen TV, Chen JK (2012) Chem Biol Drug Design 80:1–8
Nguyen TV, Chen JK, Murray V (2013) J Chromat B 913:113–122
Nguyen TV, Murray V (2013) Biomed Chromat 27:390–395
Chung LH, Murray V (2016) J Chromat B 1008:87–97
White RJ, Phillips DR (1989) Biochemistry 28:4277–4283
Gordon LK, Haseltine WA (1980) J Biol Chem 255:12047–12050
Lobachevsky PN, Martin RF (1996) Acta Oncol 35:809–815
Chem BiolLobachevsky PN (2000) Martin RF. Radiat Res 153:271–278
Cunningham R, Saporito S, Spitzer SG, Weiss B (1986) J Bacteriol 168:1120–1127
Xu YJ, Kim EY, Demple B (1998) J Biol Chem 273:28837–28844
Murray V, Kandasamy N (2012) Anti-Can Agent Med Chem 12:177–181
Inazuka M, Tahira T, Hayashi K (1996) Genome Res 6:551–557
Harris AL (2002) Nat Rev Cancer 2:38–47
Brown JM, Wilson WR (2004) Nat Rev Cancer 4:437–447
Du L, Sanchez C, Chen M, Edwards DJ, Shen B (2000) Chem Biol 7:623–642
Huang SX, Feng Z, Wang L, Galm U, Wendt-Pienkowski E, Yang D, Tao M, Coughlin JM, Duan Y, Shen B (2012) J Am Chem Soc 134:13501–13509
Acknowledgments
Support of this work by the University of New South Wales, Science Faculty Research Grant Scheme is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J.K., Murray, V. The determination of the DNA sequence specificity of bleomycin-induced abasic sites. J Biol Inorg Chem 21, 395–406 (2016). https://doi.org/10.1007/s00775-016-1349-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-016-1349-8